Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

Merck to pilot digital behavioural change programme

Will work with US digital therapeutics firm Blue Mesa Health in diabetes

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Alexa: find Novo Nordisk voice-activated diabetes tech

Hitlab challenge selects patient education firm Lighthouse for $50,000 funding

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links